The Genomic Landscape of Deubiquitinating Enzymes Across Breast Cancer Subtypes

Download

HIBIT22_paper_7.pdf

Date

2022-10

Author

Bınarcı, Büşra
Tuncer, Taner
Akman, H. Begüm

Metadata

Show full item record

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Item Usage Stats

194
views

46
downloads

Breast cancer, the most frequently diagnosed malignancy in women worldwide, is a highly heterogeneous disease on the molecular level and is classified into multiple subtypes [1]. There are 4 major subtypes of breast cancer that are grouped based on the presence/absence of hormone receptors (HR) (estrogen and progesterone receptor) and HER2 receptor which is a growth factor receptor: HR+/HER2-, HR+/HER2+, HR-/HER2-, and HR-/HER2+ [2]. Hemodynamic regulation of protein synthesis and degradation is one of the critical components of cellular physiology. Ubiquitination of proteins as a posttranslational modification is emerging as a key regulatory mechanism for regulating protein degradation and signaling activity. Ubiquitination is mediated by ubiquitin ligases and can be reverted by deubiquitinases (DUBs) [3]. DUBs are proteases that remove ubiquitin tags from substrates, therefore, involved in various cellular functions by regulating the activity and stability of their substrates. The DUB family consists of 103 members in the human genome, and these are frequently misregulated in various cancers including breast cancer [4]. DUBs have emerged as attractive therapeutic targets for the development of novel molecules in recent years as they are amongst the most druggable enzymes in the ubiquitination systems due to their enzymatic protease activities and open ubiquitin pockets [5]. Despite the large in vitro and in vivo studies, DUB profiles of each breast cancer subtype are lacking. Because of the association of the HR and HER2 receptors to tumorigenesis, each subtype requires a unique treatment strategy. Knowing the expression level and mutation types of DUBs in each subtype can give us the potential to develop the best treatment strategy against cancer. Therefore, we are conducting an in silico screen to explore genomic and transcriptomic signatures of DUBs using patients' cohort data from Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) and The Cancer Genome Atlas (TCGA) [6]. We are aiming to reveal the profile of DUBs in breast cancer subtypes to lay a foundation for developing relevant therapeutic strategies.

URI

https://hibit2022.ims.metu.edu.tr
https://hdl.handle.net/11511/101883

Conference Name

The International Symposium on Health Informatics and Bioinformatics

Collections

Graduate School of Marine Sciences, Conference / Seminar

Suggestions

OpenMETU
Core

The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer Barry, Peter; et. al. (2018-10-01) Purpose: The most significant prognostic factor in early breast cancer is lymph node involvement. This stage between localized and systemic disease is key to understanding breast cancer progression; however, our knowledge of the evolution of lymph node malignant invasion remains limited, as most currently available data are derived from primary tumors.
Detection of Possible Significant Metabolites by Comparison of Metabolic Simulation Profiles of Healthy and Breast Cancer Tissues Akkuzu Özyeşer, Selin; Bülbül, Abdullah Alper; Başaran, Gül; Sezerman, Osman Uğur (Orta Doğu Teknik Üniversitesi Enformatik Enstitüsü; 2022-10) Breast cancer is the most frequent malignancy in women worldwide and is curable in ~70–80% of patients with early- stage, non- metastatic disease. In Breast cancer there are pathways related to Luminal A breast cancer, Luminal B breast cancer, HER2 positive breast cancer, Basal like/Triple negative breast cancer. The crucial signal transduction pathways in a breast cancerous cell includes pathways like PKB (protein kinase B), MAPK (mitogen-activated protein kinase), MTOR (mammalian target of rapamycin), Fas...
Investigation of the effects of combine use of cisplatin and metformin on proliferation of prostate cancer cell lines and gstp, cyp17a1 and hexokinase II enzymes Durukan, Özlem; Adalı, Orhan; Arslan, Şevki; Department of Biochemistry (2016) Prostate cancer is the most common cancer type both in developed and developing countries. Since 2015, it has been seen as one of the main cause of death in males, both in the world and in our country. Current therapeutic approaches for prostate cancer generally have variable efficiency, develop metastasis and drug resistance, and have high toxicity to normal tissues. Hence, the searching for more effective strategies with moderate or any adverse effects for the chemopreventive intervention of those cancers...
COMPUTER AIDED DIAGNOSIS SYSTEM FOR AUTOMATIC TWO STAGES CLASSIFICATION OF BREAST MASS IN DIGITAL MAMMOGRAM IMAGES Alqudah, Ali Mohammad; Algharib, Huda M. S.; Algharib, Amal M. S.; Algharib, Hanan M. S. (2019-02-01) Breast cancer is the most frequent cancer type that is diagnosed in women. The exact causes of such cancer are still unknown. Early and precise detection of breast cancer using mammogram images or biopsy to provide the required medications can increase the healing percentage. There are much current research efforts to developed a computer aided diagnosis (CAD) system based on mammogram images for detecting and classification of breast masses. In this research, a CAD system is developed for automated segment...
A comparative study on EpCAM antibody immobilization on gold surfaces and microfluidic channels for the detection of circulating tumor cells Cetin, Didem; Okan, Meltem; Bat, Erhan; Külah, Haluk (2020-04-01) Detection of circulating tumor cells (CTCs) from the bloodstream holds great importance to diagnose cancer at early stages. However, CTCs being extremely rare in blood makes them difficult to reach. In this paper, we introduced different surface modification techniques for the enrichment and detection of MCF-7 in microfluidic biosensor applications using gold surface and EpCAM antibody. Mainly, two different mechanisms were employed to immobilize the antibodies; covalent bonding and bioaffinity interaction....

Citation Formats

B. Bınarcı, T. Tuncer, and H. B. Akman, “The Genomic Landscape of Deubiquitinating Enzymes Across Breast Cancer Subtypes,” Erdemli, Mersin, TÜRKİYE, 2022, p. 3007, Accessed: 00, 2023. [Online]. Available: https://hibit2022.ims.metu.edu.tr.